According to @ReutersBiz, European pharmaceutical shares were mostly firm even after U.S. President Donald Trump announced new tariffs on branded pharmaceutical imports effective October 1. According to @ReutersBiz, the report highlights the tariff start date but does not provide company-level details or specific tariff rates, with the immediate market response in European pharma described as largely resilient. According to @ReutersBiz, the update does not reference broader cross-asset moves or crypto market reactions, indicating no reported immediate spillover into digital assets in this dispatch. According to @ReutersBiz, the next concrete catalyst for traders is the October 1 implementation timing, which sets a clear headline-risk checkpoint for positioning and risk management.

According to @CNBC, European stocks are set to open higher following the White House’s latest tariffs news, signaling a positive risk tone at the European cash open (source: CNBC, https://www.cnbc.com/2025/09/26/europe-markets-sept-26-trumps-100percent-pharma-tariffs-ftse-100.html). CNBC links the expected higher open directly to the White House tariff developments as the immediate catalyst (source: CNBC, https://www.cnbc.com/2025/09/26/europe-markets-sept-26-trumps-100percent-pharma-tariffs-ftse-100.html). CNBC did not cite any direct impact on cryptocurrency markets in this update, which traders should note when assessing cross-asset sentiment (source: CNBC, https://www.cnbc.com/2025/09/26/europe-markets-sept-26-trumps-100percent-pharma-tariffs-ftse-100.html).

According to @CNBC, Morgan Stanley upgraded ASML and cited AI tailwinds as a key driver expected to boost the stock. According to @CNBC, the bank’s call frames AI demand as the primary catalyst behind ASML’s upside case. According to @CNBC, the report did not cite any direct cryptocurrency market implications from this upgrade.